CNSP News and Press, CNS Pharmaceuticals Inc. From 11/16/21

CNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event Live moderated video webcast discussion among members of management on Thursday, November 18th at 9:00 AM ET PR Newswire HOUSTON , Nov. 16, 2021 /PRNewswire/ -- CNS Pharmaceuticals, I...

Glioblastoma is a common and aggressive type of cancer that occurs in the spinal cord or brain. This cancer is almost twice as likely to affect males and is mostly found in adults. About 12,000 individuals are diagnosed with this cancer in the United States annually. Patients diagnosed wit...

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies - PITTSTOWN, NJ / ACCESSWIRE / November 4, 2021 / November 4, 2021 -...

For the longest time, researchers thought that the process through which cancer spread to other parts of the body, in particular the brain, was random. However, a recent study conducted by researchers at the University of Southern California has found that cancer spread to other parts of t...

A new study has found that spending too much time in space may cause brain damage . The study involved following a group of Russian cosmonauts who stayed on the International Space Station (“ISS”), which is orbiting 400 km from the planet’s surface. The study was cond...

Researchers from the Tel Aviv University have discovered that some immune cells in the body of a patient with cancer stop fighting cancer after a time and instead begin protecting the tumor. This breakthrough by the Israeli researchers could enhance the efficacy of treatments for cancer, i...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that it has been featured in a broadcast via NetworkNewsAudi...

LOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announces th...

A new study has discovered a tool that can identify cancer survivors who have syndromes that predispose them to cancer and heighten their risk of subsequent cancer development. The research, which was published in the “Journal of Clinical Oncology,” notes that the tool had pr...

An individual’s lifetime risk of developing a spinal cord or malignant brain tumor is under 1%. The American Cancer Society reveals that even when primary brain tumors do occur, more than half of them are benign, which means that they are not cancerous. Dr. Alyx B. Porter, a neuro...